Michael S. Saag

46.9k total citations · 18 hit papers
328 papers, 28.8k citations indexed

About

Michael S. Saag is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Michael S. Saag has authored 328 papers receiving a total of 28.8k indexed citations (citations by other indexed papers that have themselves been cited), including 229 papers in Infectious Diseases, 153 papers in Virology and 102 papers in Epidemiology. Recurrent topics in Michael S. Saag's work include HIV/AIDS Research and Interventions (163 papers), HIV Research and Treatment (153 papers) and HIV/AIDS drug development and treatment (146 papers). Michael S. Saag is often cited by papers focused on HIV/AIDS Research and Interventions (163 papers), HIV Research and Treatment (153 papers) and HIV/AIDS drug development and treatment (146 papers). Michael S. Saag collaborates with scholars based in United States, United Kingdom and France. Michael S. Saag's co-authors include George M. Shaw, Michael J. Mugavero, J Michael Kilby, Paul A. Volberding, Donna M. Jacobsen, Melanie Thompson, Beatrice H. Hahn, John C. Kappes, Douglas D. Richman and Xiping Wei and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Michael S. Saag

321 papers receiving 27.8k citations

Hit Papers

Antibody neutralization a... 1991 2026 2002 2014 2003 2002 2000 1998 1998 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Antibody neutralization and escape by HIV-1
    2003 1.8k citations J Michael Kilby, Michael S. Saag et al. profile →
  2. Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving Fusion Inhibitor (T-20) Monotherapy
    2002 1.3k citations J Michael Kilby, Michael S. Saag et al. profile →
  3. Antiretroviral Therapy in Adults
    2000 874 citations Michael S. Saag, Paul A. Volberding et al. profile →
  4. Antiretroviral Therapy for HIV Infection in 1998
    1998 837 citations Michael S. Saag, Paul A. Volberding et al. profile →
  5. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry
    1998 819 citations J Michael Kilby, Michael S. Saag et al. profile →
  6. Treatment for Adult HIV Infection
    2006 767 citations Michael S. Saag, Paul A. Volberding et al. profile →
  7. Treatment for Adult HIV Infection
    2004 601 citations Michael S. Saag, Paul A. Volberding et al. profile →
  8. Antiretroviral Treatment for Adult HIV Infection in 2002
    2002 573 citations Michael S. Saag, Paul A. Volberding et al. profile →
  9. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes.
    2006 552 citations Jeffrey S. A. Stringer, Jens Levy et al. PubMed profile →
  10. Treatment of Cryptococcal Meningitis Associated with the Acquired Immunodeficiency Syndrome
    1997 540 citations Michael S. Saag et al. profile →
  11. High Titers of Cytopathic Virus in Plasma of Patients with Symptomatic Primary HIV-1 Infection
    1991 505 citations Michael S. Saag, Beatrice H. Hahn et al. profile →
  12. Major expansion of CD8+ T cells with a predominant Vβ usage during the primary immune response to HIV
    1994 503 citations Michael S. Saag et al. profile →
  13. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
    2016 478 citations Michael S. Saag, Joseph J. Eron et al. profile →
  14. Comparison of Amphotericin B with Fluconazole in the Treatment of Acute AIDS-Associated Cryptococcal Meningitis
    1992 470 citations Michael S. Saag et al. profile →
  15. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
    2018 401 citations Michael S. Saag, Michael J. Mugavero et al. profile →
  16. Antiretroviral Treatment of Adult HIV Infection
    2014 352 citations Joseph J. Eron, Joel E. Gallant et al. profile →
  17. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
    2014 350 citations Michael S. Saag et al. profile →
  18. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
    2022 320 citations Joseph J. Eron, Michael S. Saag et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Michael S. Saag 19.4k 15.5k 9.5k 4.7k 3.7k 328 28.8k
Joseph J. Eron 20.8k 1.1× 17.1k 1.1× 7.0k 0.7× 3.8k 0.8× 2.4k 0.6× 465 27.9k
Margaret A. Fischl 16.5k 0.9× 12.5k 0.8× 6.8k 0.7× 3.4k 0.7× 2.0k 0.5× 268 23.5k
Diane V. Havlir 15.6k 0.8× 11.7k 0.8× 6.8k 0.7× 3.0k 0.6× 3.0k 0.8× 390 22.3k
Richard E. Chaisson 21.7k 1.1× 8.2k 0.5× 15.6k 1.6× 2.2k 0.5× 2.2k 0.6× 370 28.4k
Jeffrey N. Martin 11.7k 0.6× 11.6k 0.7× 6.7k 0.7× 5.3k 1.1× 5.7k 1.5× 340 23.5k
John W. Mellors 18.2k 0.9× 19.1k 1.2× 4.5k 0.5× 2.7k 0.6× 3.5k 0.9× 408 24.9k
Max Essex 11.7k 0.6× 12.9k 0.8× 6.8k 0.7× 1.6k 0.3× 6.7k 1.8× 548 24.2k
John Phair 11.0k 0.6× 9.5k 0.6× 7.6k 0.8× 3.0k 0.6× 4.0k 1.1× 353 22.0k
Bonaventura Clotet 16.4k 0.8× 15.3k 1.0× 5.1k 0.5× 3.6k 0.8× 3.4k 0.9× 716 24.8k
Adriano Lazzarin 12.2k 0.6× 10.9k 0.7× 6.2k 0.7× 3.4k 0.7× 2.8k 0.7× 616 20.6k

Countries citing papers authored by Michael S. Saag

Since Specialization
Citations

This map shows the geographic impact of Michael S. Saag's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael S. Saag with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael S. Saag more than expected).

Fields of papers citing papers by Michael S. Saag

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael S. Saag. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael S. Saag. The network helps show where Michael S. Saag may publish in the future.

Co-authorship network of co-authors of Michael S. Saag

This figure shows the co-authorship network connecting the top 25 collaborators of Michael S. Saag. A scholar is included among the top collaborators of Michael S. Saag based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael S. Saag. Michael S. Saag is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Colombo, Rhonda E, Maribeth H. Johnson, Gabriela Pacholczyk, et al.. (2021). Indoleamine 2,3 Dioxygenase, Age, and Immune Activation in People Living with Hiv. Journal of Investigative Medicine. 69(6). 1238–1244. 7 indexed citations
2.
Saag, Michael S.. (2019). HIV 101: fundamentals of antiretroviral therapy.. PubMed. 27(3). 123–127. 2 indexed citations
3.
Merlin, Jessica S., Sarah Young, Mallory O. Johnson, et al.. (2018). Intervention Mapping to develop a Social Cognitive Theory-based intervention for chronic pain tailored to individuals with HIV. Contemporary Clinical Trials Communications. 10. 9–16. 9 indexed citations
4.
Nance, Robin M., Heidi M. Crane, Corey Ritchings, et al.. (2018). Differentiation of Type 1 and Type 2 Myocardial Infarctions Among HIV-Infected Patients Requires Adjudication Due to Overlap in Risk Factors. AIDS Research and Human Retroviruses. 34(11). 916–921. 3 indexed citations
5.
Bilal, Usama, Mary E. McCaul, Heidi M. Crane, et al.. (2017). Predictors of Longitudinal Trajectories of Alcohol Consumption in People with HIV. Alcoholism Clinical and Experimental Research. 42(3). 561–570. 21 indexed citations
6.
Tirschwell, David, Felicia C. Chow, Kyra J. Becker, et al.. (2017). Incidence of Stroke in the US Centers for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS) Cohort (S51.008). Neurology. 88(16_supplement). 2 indexed citations
7.
Saag, Michael S.. (2016). Ledipasvir/sofosbuvir for 12 weeks in patients coinfected with HCV and HIV-1. Journal of the International AIDS Society. 19(2). 4 indexed citations
8.
Willig, Amanda L., Andrew O. Westfall, Edgar T. Overton, et al.. (2015). Obesity Is Associated with Race/Sex Disparities in Diabetes and Hypertension Prevalence, But Not Cardiovascular Disease, Among HIV-Infected Adults. AIDS Research and Human Retroviruses. 31(9). 898–904. 30 indexed citations
9.
Merlin, Jessica S., Janet M. Turan, Andrew O. Westfall, et al.. (2014). Aberrant Drug-Related Behaviors: A Qualitative Analysis of Medical Record Documentation in Patients Referred to an HIV/Chronic Pain Clinic. Pain Medicine. 15(10). 1724–1733. 16 indexed citations
10.
Burkholder, Greer, Ashutosh Tamhane, James H. Willig, et al.. (2014). Short Communication: Viral Suppression Is Associated with Increased Likelihood of Colorectal Cancer Screening Among Persons Living with HIV/AIDS. AIDS Research and Human Retroviruses. 31(5). 519–524. 6 indexed citations
11.
Tucker, Rodney, et al.. (2013). The role of palliative care in the current HIV treatment era in developed countries.. Europe PMC (PubMed Central). 21(1). 20–26. 12 indexed citations
12.
Nevin, Christa R., Inmaculada Aban, Michael J. Mugavero, et al.. (2011). The Role of Toxicity-Related Regimen Changes in the Development of Antiretroviral Resistance. AIDS Research and Human Retroviruses. 27(9). 957–963. 4 indexed citations
13.
Goldman, Jason D., Ronald A. Cantrell, Lloyd Mulenga, et al.. (2008). Simple Adherence Assessments to Predict Virologic Failure among HIV-Infected Adults with Discordant Immunologic and Clinical Responses to Antiretroviral Therapy. AIDS Research and Human Retroviruses. 24(8). 1031–1035. 71 indexed citations
14.
Saag, Michael S., Ramani Balu, Philip S. Brachman, et al.. (2007). High sensitivity of HLA-B*5701 in Whites and Blacks in immunologically-confirmed cases of abacavir hypersensitivity (ABC HSR). Murdoch Research Repository (Murdoch University). 115(2). 163–5. 8 indexed citations
15.
Kilby, J Michael, Jacob Lalezari, Joseph J. Eron, et al.. (2003). The Safety, Plasma Pharmacokinetics, and Antiviral Activity of Subcutaneous Enfuvirtide (T-20), a Peptide Inhibitor of gp41-Mediated Virus Fusion, in HIV-Infected Adults. AIDS Research and Human Retroviruses. 19(1). 83–83. 6 indexed citations
16.
Kilby, J Michael, Jacob Lalezari, Joseph J. Eron, et al.. (2002). The Safety, Plasma Pharmacokinetics, and Antiviral Activity of Subcutaneous Enfuvirtide (T-20), a Peptide Inhibitor of gp41-Mediated Virus Fusion, in HIV-Infected Adults. AIDS Research and Human Retroviruses. 18(10). 685–693. 152 indexed citations
17.
Ross, Lisa, Qiming Liao, Haitao Gao, et al.. (2001). Impact of HIV Type 1 Drug Resistance Mutations and Phenotypic Resistance Profile on Virologic Response to Salvage Therapy. AIDS Research and Human Retroviruses. 17(15). 1379–1385. 12 indexed citations
18.
Gao, Feng, Ling Yue, Michael S. Saag, et al.. (1994). HIV-1 Sequence Subtype D in the United States. AIDS Research and Human Retroviruses. 10(5). 625–627. 37 indexed citations
19.
Saag, Michael S.. (1994). Evolving Understanding of the Immunopathogenesis of HIV. AIDS Research and Human Retroviruses. 10(8). 887–892. 7 indexed citations
20.
Saag, Michael S.. (1994). Clinical Investigation of HIV Disease. AIDS Research and Human Retroviruses. 10(8). 881–881. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joseph J. Eron Breakdown of academic impact, for papers by Margaret A. Fischl Breakdown of academic impact, for papers by Diane V. Havlir Breakdown of academic impact, for papers by Richard E. Chaisson Breakdown of academic impact, for papers by Jeffrey N. Martin Breakdown of academic impact, for papers by John W. Mellors Breakdown of academic impact, for papers by Max Essex Breakdown of academic impact, for papers by John Phair Breakdown of academic impact, for papers by Bonaventura Clotet Breakdown of academic impact, for papers by Adriano Lazzarin
Rankless by CCL
2026